NCT02122913View on ClinicalTrials.gov

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 4, 2014

Primary Completion Date

February 1, 2017

Study Completion Date

April 9, 2021

Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
DRUG

Larotrectinib (Vitrakvi, BAY2757556)

BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Trial Locations (8)

15232

University of Pittsburgh, Pittsburgh

19104

University of Pennsylvania, Philadelphia

37203

Sarah Cannon Research Institute, Nashville

44106

University Hospitals Cleveland Medical Center, Cleveland

77030

University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado, Aurora

97239

Oregon Health and Science University, Portland

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02122913 - A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer | Biotech Hunter | Biotech Hunter